Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics …
S Li, J He, X Zhang, Y Cai, J Liu, X Nie… - Frontiers in …, 2022 - frontiersin.org
Objective The aim of this article is to assess the risk and potential mechanisms of
cardiovascular adverse events in patients treated with nilotinib or imatinib by conducting a …
cardiovascular adverse events in patients treated with nilotinib or imatinib by conducting a …
Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies
F Cheng, Q Xu, Q Li, Z Cui, W Li, F Zeng - Frontiers in oncology, 2023 - frontiersin.org
Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line
treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second …
treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second …
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic‐phase chronic myeloid leukemia: A study from the Registro Italiano LMC and …
Background Imatinib, dasatinib, and nilotinib are tyrosine kinase inhibitors (TKIs) approved
in Italy for frontline treatment of chronic‐phase chronic myeloid leukemia (CP‐CML). The …
in Italy for frontline treatment of chronic‐phase chronic myeloid leukemia (CP‐CML). The …
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and …
SH Cha, K Kim, YK Song - Acta Oncologica, 2023 - Taylor & Francis
Background Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase
inhibitors (TKIs) often experience cutaneous adverse events, such as rashes and pruritus. In …
inhibitors (TKIs) often experience cutaneous adverse events, such as rashes and pruritus. In …
Engineering for Biomedical Sector: A Cross-Industry Approach for the Analysis of Molecular Patterns behind Endothelial Damage Related to Leukemia Therapy
PF Ferrari, M Pettinato, M Bergamaschi… - Industrial & …, 2024 - ACS Publications
This transdisciplinary work aims to demonstrate cross-industry learning potential based on
the application of a process safety approach to the biomedical sector for specifically …
the application of a process safety approach to the biomedical sector for specifically …
[HTML][HTML] Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
C Gambacorti‐Passerini, FE Nicolini… - American Journal of …, 2022 - ncbi.nlm.nih.gov
To the Editor: A normal life expectancy for chronic myeloid leukemia (CML) patients treated
with tyrosine kinase inhibitors (TKIs) was first identified in 2011 and 2014 as a result of …
with tyrosine kinase inhibitors (TKIs) was first identified in 2011 and 2014 as a result of …
Evaluation of Time to Onset and Outcome of Cardiac Adverse Events Associated with Nilotinib using Post-Marketing Surveillance
Y Kanbayashi, A Kojima, H Wakabayashi, T Shimizu… - Oncology, 2023 - karger.com
Abstract Introduction: Cardiac adverse events (CAEs) have become a concern as serious
adverse events (AEs) of nilotinib administration. No reports have described the incidence of …
adverse events (AEs) of nilotinib administration. No reports have described the incidence of …
Clinical and Genetic studies in Chronic Myeloid Leukaemia
H Flygt - 2024 - diva-portal.org
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 2031. 73
pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-2063-2. This thesis explores …
pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-2063-2. This thesis explores …
Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance
A Kojima, H Wakabayashi, T Shimizu, M Uchida - Authorea Preprints, 2023 - karger.com
Abstract Introduction: Cardiac adverse events (CAEs) have become a concern as serious
adverse events (AEs) of nilotinib administration. No reports have described the incidence of …
adverse events (AEs) of nilotinib administration. No reports have described the incidence of …